Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  1,116 results for ""Insulin Glargine""

Your Filters

Subject : hyperglycemia
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing.

  • Authors : Fox MA; Pharmacy Services, Orlando Regional Medical Center, Orlando, Florida.; Perry MC

Subjects: Critical Illness*; Hyperglycemia/Hyperglycemia/Hyperglycemia/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*administration & dosage

  • Source: Pharmacotherapy [Pharmacotherapy] 2020 Mar; Vol. 40 (3), pp. 186-190. Date of Electronic Publication: 2020 Feb 25.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8111305 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Glycemic Control in Adult Surgical Patients Receiving Regular Insulin Added to Parenteral Nutrition vs Insulin Glargine: A Retrospective Chart Review.

  • Authors : Truong S; Department of Clinical Pharmacy, San Francisco Medical Center, University of California, San Francisco, California, USA.; Park A

Subjects: Hyperglycemia/Hyperglycemia/Hyperglycemia/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*administration & dosage ; Insulin/Insulin/Insulin/*administration & dosage

  • Source: Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition [Nutr Clin Pract] 2019 Oct; Vol. 34 (5), pp. 775-782. Date of Publisher: Wiley Country of Publication: United States NLM ID: 8606733 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-2452

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.

Subjects: Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*therapeutic use ; Diabetes Mellitus, Type 1/Diabetes Mellitus, Type 1/Diabetes Mellitus, Type 1/*drug therapy ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Aug; Vol. 20 (8), pp. 1944-1950. Date of Electronic Publication: 2018 May 07.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.

Subjects: Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*pharmacokinetics ; Diabetes Mellitus, Type 1/Diabetes Mellitus, Type 1/Diabetes Mellitus, Type 1/*drug therapy ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Feb; Vol. 20 (2), pp. 400-408. Date of Electronic Publication: 2017 Sep 26.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Glycaemic control and hypoglycaemia in people with type 2 diabetes switching from twice-daily basal insulin to once-daily insulin glargine 300 U/mL or insulin glargine 100 U/mL (EDITION 1 and EDITION 2 subgroup analysis).

  • Authors : Roussel R; INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France.; Département Hospitalo-Universitaire FIRE, Service de Diabétologie, Endocrinologie et Nutrition, UFR de Médecine, and Assistance Publique Hôpitaux de Paris, Hôpital Bichat, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control ; Hypoglycemia/Hypoglycemia/Hypoglycemia/*prevention & control

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Feb; Vol. 20 (2), pp. 448-452. Date of Electronic Publication: 2017 Sep 14.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Impact of baseline glycated haemoglobin, diabetes duration and body mass index on clinical outcomes in the LixiLan-O trial testing a titratable fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine and lixisenatide monocomponents.

  • Authors : Davies MJ; Diabetes Research Centre, University of Leicester, Leicester, UK.; Leiter LA

Subjects: Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Glycated Hemoglobin/Glycated Hemoglobin/Glycated Hemoglobin/*analysis ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2017 Dec; Vol. 19 (12), pp. 1798-1804. Date of Electronic Publication: 2017 Jul 07.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin.

  • Authors : Zhou FL; Sanofi, Bridgewater, New Jersey.; Ye F

Subjects: Cost Savings* ; Health Care Costs*; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 May; Vol. 20 (5), pp. 1293-1297. Date of Electronic Publication: 2018 Jan 24.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes (EDITION 4).

  • Authors : Home PD; Institute of Cellular Medicine - Diabetes, Newcastle University, Newcastle upon Tyne, UK.; Bergenstal RM

Subjects: Diabetes Mellitus, Type 1/Diabetes Mellitus, Type 1/Diabetes Mellitus, Type 1/*diet therapy ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control ; Hypoglycemia/Hypoglycemia/Hypoglycemia/*prevention & control

  • Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2018 Jan; Vol. 20 (1), pp. 121-128. Date of Electronic Publication: 2017 Aug 08.Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Use of Insulin Glargine in the Management of Neonatal Hyperglycemia in an ELBW Infant.

  • Authors : Hwang MJ; Department of Pediatrics, Madigan Army Medical Center, Tacoma, Washington .; Newman R

Subjects: Infant, Extremely Low Birth Weight*; Hyperglycemia/Hyperglycemia/Hyperglycemia/*drug therapy ; Hypoglycemic Agents/Hypoglycemic Agents/Hypoglycemic Agents/*therapeutic use

  • Source: Pediatrics [Pediatrics] 2018 Apr; Vol. 141 (Suppl 5), pp. S399-S403.Publisher: American Academy of Pediatrics Country of Publication: United States NLM ID: 0376422 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Read More Add to Saved list
×
Academic Journal

Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures.

  • Authors : Lingvay I; 1 Department of Internal Medicine/Endocrinology, Department of Clinical Sciences, University of Texas Southwestern Medical Center , Dallas, Texas.; Chao J

Subjects: Diabetes Complications/Diabetes Complications/Diabetes Complications/*prevention & control ; Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/Diabetes Mellitus, Type 2/*drug therapy ; Hyperglycemia/Hyperglycemia/Hyperglycemia/*prevention & control

  • Source: Diabetes technology & therapeutics [Diabetes Technol Ther] 2017 May; Vol. 19 (5), pp. 315-322. Date of Electronic Publication: 2017 May 03.Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100889084 Publication Model: Print-Electronic Cited Medium: Internet

Record details

Read More Add to Saved list
×
  • 1-10 of  1,116 results for ""Insulin Glargine""